COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

Description

Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions

Conditions

Covid19

Study Overview

Study Details

Study overview

Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions

COVID-19 Risk Assessment Hospitalization Outcomes Epidemiology Efficacy

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

Condition
Covid19
Intervention / Treatment

-

Contacts and Locations

Phoenix

Multiple Locations, Phoenix, Arizona, United States, 85016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * COVID-19 PCR positive
  • * COVID-19 PCR negative
  • * COVID-19 PCR pending
  • * COVID-19 high risk score
  • * Subjects unwilling to participate in the study before, during or after consent
  • * Patients considered unreliable by the investigator concerning the requirements for follow-up visits.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Aventyn, Inc.,

Hans A Vink, PhD, PRINCIPAL_INVESTIGATOR, Maastricht University

Michael Castro, MD, PRINCIPAL_INVESTIGATOR, Abrazo Health Network

Kris Vijay, MD, STUDY_CHAIR, Abrazo Health Network

Study Record Dates

2026-06-30